- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05019651
Acceptability and Feasibility of Apollo in Veterans With a History of PTSD (Apollo PTSD)
November 13, 2025 updated by: Lisa Brenner
Acceptability and Feasibility of Apollo Wearable System, Tuned Vibroacoustic Stimulation (TVS) in Veterans With a History of Post-traumatic Stress Disorder (PTSD)
The proposed investigation is an open label pilot study intended to establish the acceptability and feasibility of the Apollo in a population of Veterans.
Exploratory data regarding biological signatures will also be collected.
Study Overview
Detailed Description
Evaluation of Apollo requires a stepwise process in which initial aims are geared towards identifying biological signatures versus diagnosing, treating, mitigating or curing any conditions.
Towards the end of identifying potential biological signatures, we hypothesize the following.
1) Participants who use the Apollo will have an attenuated physiological stress response as measured by improved heart rate variability (HRV) compared to baseline.
2) Participants who use Apollo will have attenuated perceived psychological stress measured by lower scores on psychological correlates of acute stress when compared to baseline
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Eastern Colorado Health Care System (ECHCS)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Veterans eligible to receive care by a VA provider
- History of at least one deployment in support of Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND)
- Current diagnosis of PTSD per the Clinician Administered PTSD Scale-5 (CAPS-5)
- Willingness to wear the Apollo daily and to comply with study protocol
- Android or Apple smart phone on which the participant can download the Apollo mobile app
- Age between 18 and 65
- Ability to provide informed consent
Exclusion Criteria:
- Inability to adequately respond to questions regarding the informed consent procedure
- Currently involved in the criminal justice system as a prisoner or ward of the state
- Current (past month) alcohol or substance abuse or dependence
- Lifetime history of bipolar disorder, psychosis, or delusional disorders
- Lifetime history of oppositional defiant disorder or anti-social personality disorder
- Pregnancy
- Recent medication changes in the past 4 weeks
- A current beta blocker prescription (other than prazosin)
- Active untreated visual impairment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single Arm- Apollo Wearable System
Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation).
The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies.
Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14
The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
|
Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone.
Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day.
They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks.
They will be asked to continue to wear the device until all study data is collected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability via Credibility Scale
Time Frame: 6 +/- 2 weeks
|
The Credibility Scale is a three-item questionnaire that will be used to assess patients' sense of the Apollo Wearable Device credibility.
|
6 +/- 2 weeks
|
|
Acceptability via Expectancy Scale
Time Frame: 6 +/- 2 weeks
|
The Credibility Scale is a two-item questionnaire that will be used to assess patients' expectations of the Apollo Wearable Device.
|
6 +/- 2 weeks
|
|
Acceptability via Client Satisfaction Questionnaire (CSQ)
Time Frame: 6 +/- 2 weeks
|
Client Satisfaction Questionnaire (CSQ) is an eight-item questionnaire that will be used to assess patients' satisfaction with the intervention.
The CSQ has good reliability and validity and has frequently been used to evaluate community mental health care.
|
6 +/- 2 weeks
|
|
Acceptability via Narrative Evaluation of Intervention Interview (NEII)
Time Frame: 6 +/- 2 weeks
|
Narrative Evaluation of Intervention Interview (NEII) is a 16-item semi-structured interview that is designed to help participants evaluate and describe the process and outcome of an intervention.
|
6 +/- 2 weeks
|
|
Feasibility via Credibility Scale
Time Frame: 6 +/- 2 weeks
|
The Credibility Scale is a three-item questionnaire that will be used to assess patients' sense of the Apollo Wearable Device credibility.
|
6 +/- 2 weeks
|
|
Feasibility via via Expectancy Scale
Time Frame: 6 +/- 2 weeks
|
The Credibility Scale is a two-item questionnaire that will be used to assess patients' expectations of the Apollo Wearable Device.
|
6 +/- 2 weeks
|
|
Feasibility via Client Satisfaction Questionnaire (CSQ)
Time Frame: 6 +/- 2 weeks
|
Client Satisfaction Questionnaire (CSQ) is an eight-item questionnaire that will be used to assess patients' satisfaction with the intervention.
The CSQ has good reliability and validity and has frequently been used to evaluate community mental health care.
|
6 +/- 2 weeks
|
|
Feasibility via Narrative Evaluation of Intervention Interview (NEII)
Time Frame: 6 +/- 2 weeks
|
Feasibility will be aNarrative Evaluation of Intervention Interview (NEII) is a 16-item semi-structured interview that is designed to help participants evaluate and describe the process and outcome of an intervention.
ssessed using the Credibility/Expectancy Scales, Client Satisfaction Questionnaire (CSQ), and the Narrative Evaluation of Intervention Interview (NEII).
|
6 +/- 2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2022
Primary Completion (Actual)
June 30, 2023
Study Completion (Actual)
June 30, 2023
Study Registration Dates
First Submitted
July 16, 2021
First Submitted That Met QC Criteria
August 20, 2021
First Posted (Actual)
August 25, 2021
Study Record Updates
Last Update Posted (Estimated)
November 17, 2025
Last Update Submitted That Met QC Criteria
November 13, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-2268
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed
-
VA Office of Research and DevelopmentCompleted
-
Oregon Health and Science UniversityNational Center for Advancing Translational Sciences (NCATS); Oregon Clinical...Terminated
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
-
University of Wisconsin, MadisonCompleted
-
Wake Forest University Health SciencesWithdrawn
Clinical Trials on Apollo Wearable System
-
Michelle ThompsonThe Board of Medicine; Apollo Neuroscience, Inc.RecruitingBurnout, ProfessionalUnited States
-
Apollo Neuroscience, Inc.The Board of MedicineRecruitingStress Disorders, Post-TraumaticUnited States
-
Saint James School of MedicineCompleted
-
Joseph MaroonApollo NeuroTerminatedStress | Heart Rate VariabilityUnited States
-
J. MoccoUniversity at Buffalo; MOUNT SINAI HOSPITALCompletedIntracranial HemorrhageUnited States
-
J. MoccoUniversity at Buffalo; MOUNT SINAI HOSPITALCompletedIntracranial HemorrhageUnited States
-
Mayo ClinicErbe Elektromedizin GmbHCompletedObesityUnited States
-
Robyn T. Domsic, MD, MPHApollo NeuroscienceCompletedFatigue | Systemic Sclerosis | Raynaud PhenomenonUnited States
-
Mayo ClinicRecruitingObesity | Ulcerative ColitisUnited States
-
Ascensia Diabetes CareCompleted